# **PUBLICATIONS:**

Barbara R Haight, Susan M Learned, Celine M Laffont, Paul J Fudala, Yue Zhao, Amanda S Garofalo, Mark K Greenwald, Vijay R Nadipelli, Walter Ling, Christian Heidbreder**, Rakesh Ranjan,** et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomized, double-blind, placebo-contolled, phase 3 trial. *Lancet*, Vol. 393, 778-790, 2019.

Maes, M., Delange, J., **Ranjan, R**., Meltzer, H.Y., Desnyder, R., Cooremans, W., and Scharpe, S.: Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. *Psychiatry Research* 66: 1-11,1997.

Torem, M., **Ranjan, R.**, Gilbertson, A.: Multiple Personality Disorder without History of Childhood Trauma. Hypnos, Vol. XXIV, No. 4: 173-180, 1997.

Meltzer, H.Y., Rabinowitz, J., Lee, M.A., Cola, P.A., **Ranjan, R**., Findling, R.L. and Thompson, P.A.: Age at Onset and Gender of Schizophrenic Patients in Relation to Neuroleptic Resistance. *American Journal of Psychiatry* 154:4, 475-482, 1997.

Meltzer, H.Y. and **Ranjan, R**.: Efficacy of atypical antipsychotic drugs in treatment refractory population. In *Handbook of Experimental Pharmacology, “Antipsychotics*,” Csernansky,

J.G. (Ed), Springer-Verlag, Heidelberg, 120:333-357, 1996.

Meltzer, H.Y., Lee, M.A., **Ranjan, R**., Mason, E.A., Cola, P.A.: Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. *Psychopharmacology* 124:176 187, 1996.

**Ranjan, R**. and Meltzer, H.Y.: Acute and long-term effectiveness of clozapine in treatment resistant psychotic depression. *Biological Psychiatry* 40:253-258, 1996.

Maes, M., Gastel, A.V., **Ranjan, R**., Blockx, P., Cosyns, P., Meltzer, H.Y. and Desnyder, R.: Stimulatory effects of L-5-hydroxytryptophan on post-dexamethasone -endorphin levels in major depression. *Neuropsychopharmacology* 15(4): 340-348, 1996.

Meltzer, H.Y., Thompson, P.A., Lee, M.A. and **Ranjan, R**.: Neuropsychological deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. *Neuropsychopharmacology* 14(3S):27S-33S, 1996.

Maes, M., DeMeester, I., Scharpe, S., Desnyder, R., **Ranjan, R**., and Meltzer, H.Y.: Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. *Acta Psychiatrica Scandinavica* 93: 1-8, 1996.

Maes, M., Bosmans, E., **Ranjan, R**., Vandoolaeghe, E., Meltzer, H.Y., DeLey, M., Berghmans, R., Stans, G., and Desnyder, R.: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs, *Schizophrenia Research* 21:39-50, 1996.

Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Bandoolaeghe, E., **Ranjan, R**. and Desnyder, R.: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferring receptor in major depression. *Journal of Affective Disorders* 34:301-309, 1995.

Meltzer, H.Y., **Ranjan, R**., Lee, M.A., Kennedy, J.: Emerging clinical uses of clozapine. *Reviews in Contemporary Pharmacolotherapy*: Emerging Clinical Claims for Clozapine, S. Johnson

and F.N. Johnson (Eds). Marius Press, RICP, Lancaster United Kingdom, 6:187-196, 1995.

Maes, M., Cooremans, W., Delanghe, J., Scharpe, S., Wauters, A. Neels, H., D’Hondt, P., Peeters, D., Cosyns, P., **Ranjan, R**., Bosmans, E., DeMeyer, F., Elkis, H., and Desnyder, R.: Components of biological variation in plasma haptoglobin: Relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor. *Clinica Chimica Acta* 239(1): 23-35, 1995.

**Ranjan, R**. And Meltzer, H.Y.: Clozapine and Mood Disorders. *The Italian Journal of Psychiatry and Behavioral Sciences* 1:23-27,1995.

Meltzer, H.Y. and **Ranjan, R.**: Valproic acid treatment of clozapine-induced myoclonus. *American Journal of Psychiatry*, 151:1246-1247, 1994.

Meltzer, H.Y., Lee, M.A. and **Ranjan, R**.: Recent advances in the pharmacotherapy of schizophrenia. *Acta Scandinavica Psychiatrica*, 90: (Suppl 384): 95-101, 1994.

Meltzer, H.Y., Lee, M.A., **Ranjan, R**.: Risperidone: A matter of dosage. *Innovations & Research*, 3(1): 13-14, 1994.

# **BOOK REVIEWS:**

#

De Angelis, Beverly: Shadows on the Porch: A Cleveland memoir of survival and three generations of mental illness. Foreword and Afterword by **Ranjan, R**. Book was written by the mother of a patient of Dr. Ranjan and was published in 2019.

# **ABSTRACTS:**

Stensland, M. D., Nyhuis, A., Faries, D., & **Ranjan, R**. Cost-utility of olanzapine vs. Divalproex in the treatment of manic,mixed, and hypomanic symptoms of bipolar disorder. Paper presented at the *US Psychiatric and Mental Health Congress*, 2008, October 31.

Stensland, M. D., Nyhuis, A., Jamal, H. H., & **Ranjan, R**. Impairment in quality of life and long-term improvements for individuals with elevated mood from bipolar

disorder treated with olanzapine or divalproex in clinical practice. Paper presented at the

*Collegium Internationale Neuro-Psychopharmacologicum:* 2006, July10-13.

Stensland, M.D., **Ranjan, R.**, Faries, D., Zhu, B., and Houston, J.: The Effectiveness of Olanzapine vs Divalproex in Clinical Practice: A 1-Year Study of the Treatment of Mixed, Manic, and Hypomanic Episodes of Bipolar Disorder. *New Research Abstracts, American Psychiatric Association at Annual Meeting*: 247-248, 2006, May 25.

**Ranjan, R.**, Stensland, M.D., and Zhu, B.: Common Psychiatric Comorbidities in Patients with Bipolar Disorder and Families. *US Psychiatric & Mental Health Congress, Research Abstract and Presentation Book, November 7-11, 2005*: 8, 2005.

**Ranjan, R**., Lee, M.A. and Meltzer, H.Y.: Effect of clozapine on negative symptoms.

*Psychopharmacology Bulletin* 31(3): 607, 1995.

**Ranjan, R**., Lee, M.A. and Meltzer, H.Y.: Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia. *Biological Psychiatry*

37(9):678-679, 1995.

Meltzer, H.Y. and **Ranjan, R**: Ipsapirone-induced cortisol response and its relation to negative symptoms in schizophrenia. *Society for Neuroscience Abstracts* 21, 1995.

**Ranjan, R**. and Meltzer, H.Y.: Relationship between types of symptomatology in schizophrenia and neuroleptic-responsivity. *Schizophrenia Research* 11(2):185, 1994.

**Ranjan, R**., Meltzer, H.Y., and Maes, M.: The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. *Schizophrenia Research* 11(2):115, 1994.

Okayli, G., **Ranjan, R**., and Meltzer, H.Y.: The reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia. *Schizophrenia Research* 11(2): 103-104, 1994.

# **PRESENTATIONS:**

Cost-utility of olanzapine vs. Divalproex in the treatment of manic, mixed, and hypomanic symptoms of bipolar disorder. Paper presented at the US Psychiatric and Mental Health Congress, San Diego, CA. 2008, October 31.

Impairment in Qualify of Life and Long-term Improvements for Individuals with Elevated Mood from Bipolar Disorder Treated with Olanzapine or Divalproex in Clinical Practice: Poster presentation at the XXVth CINP 2006 Chicago Congress, Chicago, July 10-13/2006.

The Effectiveness of Olanzapine vs Divalproex in Clinical Practice: A 1-Year Study of the Treatment of Mixed, Manic, and Hypomanic Episodes of Bipolar Disorder: Poster presentation at the American Psychiatric Association Annual Meeting, Toronto, Canada, May 20-25/2006.

Common Psychiatric Comorbidities in Patients with Bipolar Disorder and Families: Poster presentation at the US Psychiatric & Mental Health Congress, Las Vegas, November 7-10/2005.

Is Clozapine Limited Only to Schizophrenia?: Workshop presentation at the 17th Annual NAMI Convention, Albuquerque, New Mexico, May/1997.

Effect of Clozapine on Negative Symptoms: Poster presentation at the 35th Annual NCDEU (NIMH) Meeting, Orlando, Florida, May-June/1995.

Effect of MK-212, a Centrally Acting Serotonin Agonist on Prolactin, Cortisol and Body Temperature in Schizophrenia: Poster presentation at the 50th Annual Meeting and Scientific Program of the Society of Biological Psychiatry, Miami, Florida, May/1995.

Positive and Negative Symptom Schizophrenias - Myths and Realities: Grand Rounds Presentation at the Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, May/1994.

Management of Neuroleptic Side Effects: Grand Rounds Presentation at Western Reserve Psychiatric Hospital, Northfield, Ohio, June/1994.

Relationship Between Positive and Negative Symptoms in Schizophrenics and Neuroleptic- Responsivity: Poster presentation at the 7th Biennial Winter Workshop on Schizophrenia in Les Diablerets, Switzerland, January/1994.

The Cimetidine-induced Increase in Prolactin Secretion in Schizophrenia: Effect of Clozapine. Poster presentation at the 7th Biennial Winter Workshop on Schizophrenia in Les Diablerets, Switzerland, January/1994.

The Reduction of Suicidality During Clozapine treatment in Neuroleptic-Resistant Schizophrenia: Poster presentation at the 7th Biennial Winter Workshop on Schizophrenia in Les Diablerets, Switzerland, January/1994.

Chlorprothixene in Treatment of Trauma-Related Flashbacks: Seventh Regional Conference on Trauma, Dissociation and Multiple Personality, Akron, Ohio, April/1992